Preliminary Results of a Phase II Study of Retifanlimab (PD-1 Inhibitor) Plus or Minus Epacadostat (IDO1 Inhibitor) in Combination with Bevacizumab and Hypofractionated Radiotherapy for Recurrent Glioblastoma: NCT03532295.
NEURO-ONCOLOGY（2024）
关键词
Radioimmunotherapy,Glioblastoma,Radiotherapy,Biomarkers for Immunotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要